New FDA Nicotine Pouch Authorizations Add More Choices to the U.S. Market

Nicotine pouches continue to gain attention in the U.S., and the Food and Drug Administration has recently expanded the group of products that can legally be marketed in the country.

The FDA authorized 11 new ZYN ULTRA nicotine pouch products from Swedish Match USA on August 21, 2026. The decision followed another authorization earlier in August covering four new on! nicotine pouch products from Helix Innovations.

The two decisions add new flavors and nicotine strengths while offering another look at how the FDA is handling the rapidly developing nicotine pouch category.

ZYN ULTRA Expands Its Lineup

The latest ZYN decision includes a wide range of 9 mg products along with an 11 mg Smooth option.

The authorized ZYN ULTRA lineup includes Chill, Citrus, Cool Mint, Deep Freeze, Menthol, Peppermint, Smooth, Spearmint, Wintergreen Chill, and Wintergreen. Smooth is offered in both 9 mg and 11 mg strengths.

The broader selection gives the ZYN brand additional room to appeal to different preferences. Some consumers may be more interested in mint and menthol flavors, while others may prefer citrus or wintergreen profiles.

The higher nicotine strengths also stand out because they expand the range of options available within an increasingly competitive pouch market.

Still, the FDA's authorization should not be confused with a declaration that these products are safe.

The agency specifically states that marketing authorization does not mean a tobacco product is “FDA approved.” Nicotine remains addictive, and the FDA continues to warn that all tobacco products can carry health risks.

on! Adds Fruit, Coffee and Seasonal Flavors

The ZYN announcement was preceded by an FDA authorization involving four additional on! products.

The newly authorized products include Rich Berry at 2 mg, Cappuccino at 2 mg, Cappuccino at 4 mg, and Autumn Spice at 2 mg.

The flavors show how manufacturers are moving beyond the traditional mint-heavy image associated with nicotine pouches. Berry, coffee, and seasonal flavor concepts give the category a wider range of profiles.

The different nicotine strengths also allow manufacturers to target different preferences within the same general product category.

That variety has become increasingly important as more nicotine pouch products make their way through the regulatory process.

What the FDA Actually Evaluates

Nicotine strength is only one piece of the FDA's review.

When evaluating nicotine pouch applications, the agency considers factors including product design, formulation, materials, and characteristics that can affect how nicotine is delivered and absorbed.

The FDA also examines harmful and potentially harmful constituents.

In its recent evaluations, the agency determined that the newly authorized products contained lower levels of most harmful and potentially harmful constituents compared with other oral and smokeless tobacco products. Some constituents were present at levels too low to quantify.

That finding is part of the FDA's broader population-level analysis rather than a statement that nicotine pouches are risk-free.

Complete Switching Is a Key Part of the FDA's Analysis

The potential benefits of nicotine pouches are primarily discussed in relation to people who already use traditional tobacco products.

According to the FDA, adults who smoke cigarettes or use smokeless tobacco and completely switch to authorized nicotine pouches may reduce their exposure to many harmful chemicals.

However, switching is different from simply adding another nicotine product to an existing habit.

The FDA has emphasized that people who continue smoking while also using nicotine pouches do not receive the same degree of potential risk reduction associated with completely switching away from combustible tobacco.

That distinction is likely to remain important as nicotine pouches become more common.

The FDA's Nicotine Pouch Pilot Program

The recent authorizations are also connected to changes in the FDA's review process.

The agency has been using a nicotine pouch pilot program designed to make parts of the premarket tobacco application process more efficient. The FDA says the program has helped resolve issues more quickly, reduce response times involving deficiency letters, and improve the efficiency of scientific reviews.

The agency intends to use lessons from the pilot when handling other premarket applications.

For manufacturers, a more streamlined process could make the regulatory pathway easier to navigate. For consumers, it could eventually mean a larger selection of products that have gone through the required federal review.

The Authorized Market Is Getting Larger

After authorizing the 11 ZYN ULTRA products, the FDA said 43 nicotine pouch products had received marketing authorization in the United States.

That represents a significant expansion from the relatively small number of products that initially dominated the category.

The FDA has also made clear that products without the required authorization can be subject to enforcement. As the number of authorized products grows, the distinction between legally marketed products and unauthorized products becomes increasingly important.

More Competition Could Shape the Next Phase

The latest ZYN and on! decisions point toward a nicotine pouch market that is becoming more diverse.

Manufacturers are competing through nicotine strengths, flavor choices, product design, and brand positioning rather than relying on a single type of pouch.

The FDA's role is equally important. The agency is not simply counting nicotine milligrams or comparing flavors. Its review considers how products are formulated, how nicotine is delivered, what chemicals are present, and how the products could affect both existing tobacco users and people who do not currently use tobacco.

For the industry, the recent authorizations represent another step toward a more established nicotine pouch market.

For consumers, they mean additional products are now legally authorized for marketing in the United States. At the same time, the FDA's warning remains clear: authorization is not the same thing as safety, and nicotine products can still create dependence and health risks.